Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted non-qualified stock option awards to purchase an aggregate of 739,750 shares of its Class A common stock to 8 new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan (the "2023 Inducement Plan"). The stock options were granted as inducements material to the new employees becoming employees of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si (or following a bona fide period of non-employment), as an inducement material to such individuals' entering into employment with Quantum-Si, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $3.24 per share, which is equal to the closing price of Quantum-Si's Class A common stock on The Nasdaq Global Market on July 17, 2023, the date of grant of the options. Each option will vest over a four-year period, with 25% of the shares vesting on the last day of the calendar quarter that is 12 months after the employee's start date and the remaining shares vesting monthly over the following 36-months, subject to each employee's continued employment with Quantum-Si on such vesting dates. The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing CompanyTM, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.


These press releases may also interest you

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...

at 12:18
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 11:10
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform. Panda Health...

at 10:12
AnX Robotica, the leader in advanced gastrointestinal visualization technologies, is happy to announce the appointment of two industry veterans to the leadership team....

at 07:13
Webblogic®, a pioneer in medical device manufacturing technology, is set to launch its comprehensive range of advanced manufacturing and packaging equipment specifically designed for the Medical Device, Pharma, and Life Sciences industries. In...



News published on and distributed by: